DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
OTHER
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer
BREAST
(Journal) Frontiers in Oncology
2023
PRIMED
A phase 2 trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED Study
BREAST
ESMO Breast
2023
PHERGAIN (sub-study)
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): An exploratory analysis of the PHERGain trial
BREAST
ESMO
2023
PARSIFAL
PARSIFAL-LONG: Extended follow-up of hormone receptorpositive/HER2-negative advanced breast cancer patients treated
with fulvestrant and palbociclib vs letrozole and palbociclib in the
PARSIFAL study
BREAST
SABCS
2023
DEBBRAH
Trastuzumab Deruxtecan in Patients with Unstable Central Nervous System Involvement from HER2-low advanced Breast Cancer: The DEBBRAH Trial
BREAST
SABCS
2022
CALADRIO
Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
BREAST
ESMO Breast
2022
PECATI
A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
THYMIC
ESMO
2022
REVERT
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
BREAST
(Journal) Cancers
2022
METALLICA
Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study.
BREAST
SABCS
2022
REVERT
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT).
BREAST
ESMO
2022
ZZFIRST
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide(EZ) and talazoparib (TALA) for the treatment of metastatichormone-naïve prostate cancer (mHNPC): ZZFIRST
PROSTATE
ASCO GU
2022
ORPHEUS
A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS
PENILE
ASCO GU
2022
Other MEDSIR related articles
